Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

ClinicalTrials.gov ID: NCT04938232

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04938232. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: * Ipilimumab * Nivolumab

Study identification

NCT ID: NCT04938232
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Dana-Farber Cancer Institute; Other
Enrollment: 13 participants

Conditions and interventions

Conditions

Interventions

Nivolumab Drug
Ipilimumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2021 (Actual)
Primary completion: Apr 1, 2024 (Actual)
Completion: Aug 1, 2027 (Estimated)
Last update posted: Sep 16, 2026

2021 – 2027

United States locations

U.S. sites: 4
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of Chicago Medicine	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04938232, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 16, 2026 · Synced Nov 11, 2026